

## Special Issue

# Advances in Cancer Vaccines as Promising Immuno-Therapeutics

### Message from the Guest Editor

The increasing occurrence of cancer highlights the necessity for effective pharmaceuticals to treat various types of cancer. Immunotherapy has significantly influenced cancer treatment over the last decade, offering lasting remissions and prolonged survival for some patients. Various immunotherapies like monoclonal antibodies, checkpoint inhibitors, vaccines, and CAR-T cell therapy are employed. Cancer vaccines are a promising approach in solid tumor immunotherapy, activating anti-tumor immunity through tumor antigens. Ideal vaccines could counter immune suppression and evoke both humoral and cellular immunity. This Special Issue explores advancements in cancer vaccines for diverse tumor treatments. We are pleased to invite you to submit original research, reviews and perspective articles that cover, but are not limited to, the following subtopics:

- Advances in the identification of neo-antigens for cancer vaccines
- Advances in the adjuvants for cancer vaccines
- Advances in delivering systems for cancer vaccines
- Advances in cancer vaccine platforms
- The efficacy of cancer vaccines alone or in combination with other immunotherapy approaches in pre-clinical models.

---

### Guest Editor

Dr. Ling Ni

Institute for Immunology and School of Medicine, Tsinghua University, Medical Research Building, Beijing, China

---

### Deadline for manuscript submissions

closed (31 March 2025)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/181369](https://mdpi.com/si/181369)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

---

### Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College  
Roosevelt, 4331 CB Middelburg, The Netherlands

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).